Sophiris Bio, Inc. (NASDAQ:SPHS)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Friday. They presently have a $6.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 157.51% from the stock’s previous close.

A number of other equities analysts have also recently commented on the company. Maxim Group set a $6.00 target price on Sophiris Bio and gave the stock a “buy” rating in a report on Monday, August 14th. ValuEngine cut Sophiris Bio from a “hold” rating to a “sell” rating in a report on Tuesday, June 13th. Finally, Rodman & Renshaw reiterated a “buy” rating and issued a $6.00 target price on shares of Sophiris Bio in a report on Thursday, June 1st. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $6.60.

Sophiris Bio (NASDAQ SPHS) traded up 2.19% during mid-day trading on Friday, hitting $2.33. The stock had a trading volume of 255,478 shares. The stock’s 50-day moving average price is $2.00 and its 200-day moving average price is $2.33. The stock’s market cap is $70.16 million. Sophiris Bio has a 12 month low of $1.80 and a 12 month high of $3.48.

TRADEMARK VIOLATION WARNING: “HC Wainwright Reaffirms “Buy” Rating for Sophiris Bio, Inc. (SPHS)” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at

A hedge fund recently bought a new stake in Sophiris Bio stock. Mesirow Financial Investment Management Inc. acquired a new stake in shares of Sophiris Bio, Inc. (NASDAQ:SPHS) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 54,510 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Mesirow Financial Investment Management Inc. owned 0.18% of Sophiris Bio as of its most recent SEC filing. 6.01% of the stock is owned by institutional investors and hedge funds.

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Analyst Recommendations for Sophiris Bio (NASDAQ:SPHS)

Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with's FREE daily email newsletter.